Daiichi Sankyo
Daiichi Sankyo Italia S.p.A. is committed to innovation, patient care, and research, focusing on therapeutic solutions in cardiovascular, oncology, and other medical fields. The company emphasizes ethics, compliance, sustainability, and social engagement, actively participating in research projects, social initiatives, and advocacy to improve health outcomes and promote sustainability in healthcare. With a rich history dating back to its origins in Japan and a strong presence in Europe, Daiichi Sankyo aims to become a global healthcare company that contributes to sustainable development.
Industries
Nr. of Employees
Very Large (1000+)
Daiichi Sankyo
Daiichi Sankyo Italia S.p.A.
Patents
Products
Clinical‑stage oncology therapeutics including targeted biologics and ADCs
Clinical‑stage oncology agents developed using targeted biologic modalities and antibody‑drug conjugate technology, evaluated across early‑phase dose‑finding and later‑phase clinical studies in multiple solid tumours.
Oral anticoagulant therapies (direct factor‑Xa inhibitors)
Oral anticoagulant agents developed and evaluated in randomized clinical trials and large post‑authorization registries for prevention of stroke in atrial fibrillation and treatment of thromboembolic disease.
Lipid‑lowering therapeutics and fixed‑dose combinations
Oral lipid‑lowering agents, including inhibitors of cholesterol synthesis pathways and fixed‑dose combinations with absorption inhibitors, developed and evaluated in clinical studies and outcomes trials to reduce LDL cholesterol and cardiovascular risk.
Clinical‑stage oncology therapeutics including targeted biologics and ADCs
Clinical‑stage oncology agents developed using targeted biologic modalities and antibody‑drug conjugate technology, evaluated across early‑phase dose‑finding and later‑phase clinical studies in multiple solid tumours.
Oral anticoagulant therapies (direct factor‑Xa inhibitors)
Oral anticoagulant agents developed and evaluated in randomized clinical trials and large post‑authorization registries for prevention of stroke in atrial fibrillation and treatment of thromboembolic disease.
Lipid‑lowering therapeutics and fixed‑dose combinations
Oral lipid‑lowering agents, including inhibitors of cholesterol synthesis pathways and fixed‑dose combinations with absorption inhibitors, developed and evaluated in clinical studies and outcomes trials to reduce LDL cholesterol and cardiovascular risk.
Services
Web‑based channel for submission and management of suspected adverse reactions for marketed medicines.
Programmatic mechanism to provide regulated access to therapies for eligible patients outside normal commercial distribution.
Coordination of collaborative research projects, provision of translational research infrastructure and support for multi‑site studies.
On‑site preclinical and translational research services using tissue and cell models to support target validation and early testing.
Organization and delivery of community screening events, public education campaigns and patient‑facing materials for disease prevention and early detection.
Online programs and digital tools to support chronic disease self‑management, adherence and remote patient engagement.
Web‑based channel for submission and management of suspected adverse reactions for marketed medicines.
Programmatic mechanism to provide regulated access to therapies for eligible patients outside normal commercial distribution.
Coordination of collaborative research projects, provision of translational research infrastructure and support for multi‑site studies.
On‑site preclinical and translational research services using tissue and cell models to support target validation and early testing.
Organization and delivery of community screening events, public education campaigns and patient‑facing materials for disease prevention and early detection.
Online programs and digital tools to support chronic disease self‑management, adherence and remote patient engagement.
Expertise Areas
- Clinical trial management and outcomes research
- Real‑world evidence and registry design
- Oncology discovery and antibody‑drug conjugate development
- Cardiovascular therapeutics and outcomes trials
Key Technologies
- Antibody‑drug conjugates and targeted monoclonal antibody platforms
- Targeted biologic development against tumour biomarkers
- Randomized clinical trial methodologies (Phase I–III) and dose‑escalation designs
- Large‑scale post‑authorization registry design and real‑world analytics
News & Updates
Awareness event on stroke prevention and treatment.
A report highlighting cardiovascular diseases as the leading cause of death in Italy.
Awareness event on stroke prevention and treatment.
A report highlighting cardiovascular diseases as the leading cause of death in Italy.